Mapara Khubaib Y, Stevenson Charles B, Thompson Reid C, Ehtesham Moneeb
Department of Neurological Surgery, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Neurosurg Clin N Am. 2007 Jan;18(1):71-80, ix. doi: 10.1016/j.nec.2006.10.001.
Stem cell therapy represents a promising new therapeutic modality for infiltrative gliomas. The promise of this emerging technology centers on the potent migratory tropism exhibited by stem cells for disseminated foci of intracranial pathologic findings. This important characteristic, which has been validated in a wide set of preclinical studies, forms a foundation for the use of transplanted stem cell populations as vehicles for the delivery of tumor-toxic molecules to sites of intracranial tumor. Nevertheless, although experimental models using this technique to target brain tumors have shown encouraging results, many concerns and questions remain to be addressed before realistic clinical implementation of this strategy can begin. Key among these are an inadequate understanding of the specific tropic mechanisms that govern stem cell migration toward invasive tumors and the need to identify appropriate tissue sources and culture processes for the generation of adequate therapeutic stem cell populations. Despite these limitations, the use of stem cells as vectors for the treatment of brain tumors holds significant promise and may prove to be an important therapeutic modality for patients with malignant glioma.
干细胞疗法是浸润性胶质瘤一种有前景的新治疗方式。这项新兴技术的前景集中在干细胞对颅内病理发现的播散病灶所表现出的强大迁移嗜性。这一重要特性已在大量临床前研究中得到验证,为利用移植的干细胞群体作为向颅内肿瘤部位递送肿瘤毒性分子的载体奠定了基础。然而,尽管使用该技术靶向脑肿瘤的实验模型已显示出令人鼓舞的结果,但在该策略能够实际临床应用之前,仍有许多问题和担忧有待解决。其中关键的问题包括对控制干细胞向侵袭性肿瘤迁移的特定嗜性机制理解不足,以及需要确定合适的组织来源和培养方法以产生足够的治疗性干细胞群体。尽管存在这些局限性,但将干细胞用作治疗脑肿瘤的载体仍具有重大前景,可能成为恶性胶质瘤患者的一种重要治疗方式。